X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CTIM-76, is a bispecific antibody incorporating highly selective CLDN6 binding arm and CD3 binding single-chain Fv domain in an IgG format with a silenced Fc that is designed to be functionally monovalent to avoid aberrant T-cell activation and to enhance the safety profile.
Lead Product(s): CTIM-76
Therapeutic Area: Oncology Product Name: CTIM-76
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
Under the terms of the agreement, Integral Molecular will provide an exclusive worldwide license to CARTEXELL to use the panel of high-affinity, high-specificity, and fully humanized CLND18.2 MAbs for the development of CAR-T cell therapies against solid tumors.
Lead Product(s): CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cartexell
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 15, 2022
Details:
The partnership combines Integral Molecular’s experience in antibody discovery and mRNA immunization with Optimeos’ technology for nanoparticle-based drug delivery systems having nanoparticle-based DNA Therapy.
Lead Product(s): Nanoparticle-based DNA Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Optimeos Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 08, 2022
Details:
Under the terms of the agreement, Integral Molecular will provide an exclusive license to AstraZeneca for a collection of highly specific monoclonal antibodies for use in oncology. AstraZeneca will be solely responsible for all research, development, and commercial activities.
Lead Product(s): Monoclonal Antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 03, 2021
Details:
Integral Molecular has produced the most extensive catalog of SARS-CoV-2 pseudotyped reporter virus particles (RVPs), currently over 65 variants, which enables neutralizing antibodies or serum to be assessed in accordance with recent FDA .
Lead Product(s): SARS-CoV-2 Pseudotyped Reporter Virus Particles
Therapeutic Area: Infections and Infectious Diseases Product Name: SARS-CoV-2 RVPs
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2021
Details:
The partnership will leverage Integral Molecular's industry-leading platform for antibody discovery and include novel targets in cancer and autoimmune diseases.
Lead Product(s): Long-acting Therapeutic antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Optimeos
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
